Clinical Trial Update: Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease [Phase 3]

View source ↗

Summary

A Phase 3 study evaluated ipratropium bromide/salbutamol delivered by the Respimat inhaler against ipratropium bromide Respimat, Combivent inhalation aerosol, a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Combivent Inhalation Aerosol (ipratropium bromide/albuterol)
• Ipratropium bromide (Respimat) (ipratropium bromide)
• Ipratropium bromide/salbutamol (Respimat) (ipratropium bromide/salbutamol)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED